Aptar expands pharma manufacturing in Mumbai
- Mumbai site will add local production of pMDI valves, breath‑actuated systems and multi dose nasal spray systems.
- Manufacturing footprint in Mumbai increases to 11,300 m² with added molding capability alongside existing assembly operations.
- Expanded operations were inaugurated on October 5, 2026, by the Aptar Board Chair and Executive Committee members.
- Aptar has operated in India since 1998, adding a Rabale assembly facility in 2012, a Hyderabad CPG manufacturing site in 2020, and a Taloja pharma site in 2023.
Expansion scope
The Mumbai site will add local production of several pharma inhalation technologies, including Aptar’s pressurized metered dose inhaler (pMDI) valve, breath‑actuated systems and multi dose nasal spray systems. The expansion adds molding capability to the site’s existing assembly operations.
Capacity and local role
With the investment, the Mumbai manufacturing footprint has increased to 11,300 m². Aptar says the broadened site role will support evolving customer needs and enhance local capability and supply resilience to serve customers in India and across Southeast Asia with greater proximity.
Timeline and network
Aptar established a commercial presence in Mumbai in 1998, opened a Rabale assembly facility in 2012 and a Hyderabad manufacturing site for CPG products in 2020. A state‑of‑the‑art pharma site opened in Taloja in 2023. The expanded Mumbai operations were inaugurated on October 5, 2026.
Strategic rationale
Company leadership framed the investment as part of a long‑term strategy to deepen engagement in India, citing the market’s dynamics and growth potential. Aptar noted India’s rapid urbanization, expanding healthcare access, and investments in manufacturing and digital infrastructure as drivers for further opportunity.
Source: Aptar